ee

Registreeru
Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele.

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・CRISPR Therapeutics AG
Search

CRISPR Therapeutics AG

Suletud

Sektor Tervishoid

44.58 -1.26

Osta

Hinna uuendus 6. sept 2024, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.34

Max

44.68

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+65.84 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. nov 2024

Uudiste sentiment

By Acuity

50%

50%

114 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

44.04 / 48.31 Toetus ja vastupanu

CRISPR Therapeutics AG Graafik

Seotud uudised

8. dets 2023, 20:56 UTC

Suurimad hinnamuutused turgudel

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

DJ

Loe

1. nov 2023, 10:14 UTC

Suurimad hinnamuutused turgudel

Crispr Therapeutics Shares Rally Premarket After Favorable FDA Panel Meeting

DJ

Loe

11. apr 2024, 14:46 UTC

Omandamised, ülevõtmised, äriostud

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

DJ

Loe

8. dets 2023, 18:45 UTC

Peamised uudised

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

DJ

Loe

8. dets 2023, 16:45 UTC

Peamised uudised

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

DJ

Loe

8. dets 2023, 16:21 UTC

Peamised uudised

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ

DJ

Loe

24. nov 2023, 12:00 UTC

Peamised uudised

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

CRISPR Therapeutics AG Prognoos

Hinnasiht

By TipRanks

65.84% tõus

12 kuu keskmine prognoos

Keskmine 74 USD  65.84%

Kõrge 105 USD

Madal 30 USD

Põhineb 18 Wall Streeti analüütiku instrumendi CRISPR Therapeutics AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

10

Osta

6

Hoia

2

Müü

Põhineb 18 analüütiku instrumendi CRISPR Therapeutics AG aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

44.04 / 48.31Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Bearish Evidence

All events are bearish.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

114 / 365 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

902.74

↓-0.9%

UNH

UnitedHealth Group Inc

596.8

↑ +0.31%

NVO

Novo Nordisk A-S

131.05

↑ +0.18%

JNJ

Johnson and Johnson

164.37

↓-0.29%

ABBV

AbbVie Inc

193.18

↑ +0.34%